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Pharmacomechanical Therapy for Deep-Vein Thrombosis
To the Editor: Regarding the recently published 
trial by Vedantham et al. (Dec. 7 issue),1 we wish 
to comment on the results that show an apparent 
lack of effectiveness of pharmacomechanical 
catheter-directed thrombolysis in preventing the 
post-thrombotic syndrome in patients with acute 
proximal deep-vein thrombosis. Only 58% of 
the patients had deep-vein thrombosis involving 
the iliac or common femoral veins, whereas 42% 
had femoral deep-vein thrombosis, which is as-
sociated with a lower risk of the post-thrombotic 
syndrome.2 In addition, a high percentage of pa-
tients (28%) received a venous stent (vs. 5.7% of 
the patients in the CAVENT [Catheter-Directed 
Venous Thrombolysis in Acute Iliofemoral Vein 
Thrombosis] trial3). We wonder whether stent 
occlusion may have contributed to a higher inci-
dence of the post-thrombotic syndrome in the 
pharmacomechanical-thrombolysis group than 
in the control group. Finally, various nonstandard-
ized methods of pharmacomechanical catheter-
directed thrombolysis were used, which makes 
interpretation difficult. Despite all these factors, 
the incidence of moderate-to-severe post-throm-
botic syndrome was substantially lower in the 
pharmacomechanical-thrombolysis group than 
in the control group, and there were similar rates 
of major bleeding events at 24 months in the two 
groups. Given these issues, we believe that the 
outcomes of this trial are not generalizable. 
However, this trial does highlight the need for 
further studies with careful selection of patients 
and a more standardized approach.
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The authors reply: Patients with femoral deep-
vein thrombosis were included in our trial be-
cause they also are at high risk for the post-
thrombotic syndrome (which occurred in our 
trial in 44% of the patients with femoral deep-
vein thrombosis vs. 50% of those with iliofemo-
ral deep-vein thrombosis).1 Even in patients with 
iliofemoral deep-vein thrombosis, pharmacome-
chanical thrombolysis did not prevent the post-
thrombotic syndrome (which occurred in 49% of 
the patients with iliofemoral deep-vein throm-
bosis in the pharmacomechanical-thrombolysis 
group and in 51% of those in the control group). 
However, pharmacomechanical thrombolysis re-
sulted in a lower rate of moderate-to-severe post-
thrombotic syndrome and in less severity of the 
symptoms and signs of the post-thrombotic syn-
drome than was observed in the control group. 
These benefits appeared to be confined to pa-
tients with iliofemoral deep-vein thrombosis.
The thrombolytic methods used in this trial 
were standardized and reflected contemporary 
practice in the United States.2 All the operators 
were credentialed, and there were rigorous re-
quirements for thrombolytic-drug administration 
and device use. Per accepted practice, stenting 
of residual iliac-vein lesions causing a reduction 
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of more than 50% in the vein diameter, a pres-
sure gradient of more than 2 mm Hg, or robust 
collateral filling was encouraged.3,4 In the ab-
sence of a convincingly higher rate of recurrent 
deep-vein thrombosis in the pharmacomechanical-
thrombolysis group than in the control group, 
it is unlikely that stent thrombosis was an im-
portant contributor to the post-thrombotic syn-
drome. The broad inclusion criteria, contempo-
rary thrombolytic methods, and accommodation 
of physician expertise that were used in our trial 
support the generalizability of its results.
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Pleural Disease
To the Editor: With regard to the article by 
Feller-Kopman and Light (Feb. 22 issue),1 the dis-
tinction between spontaneous pneumothorax that 
occurs in apparently healthy persons and pneu-
mothorax caused by preexisting pulmonary dis-
ease may seem arbitrary in terms of treatment, 
but an important aspect of the management of 
this condition is an evaluation for genetic dis-
orders.
A total of 10% of patients with spontaneous 
pneumothorax have a family history of pneumo-
thorax.2 Heterozygous mutations in the tumor-
suppressor gene FLCN predispose to the Birt–
Hogg–Dubé syndrome, which is the most 
common genetic disorder in persons with fa-
milial pneumothorax. This syndrome, which is 
identified in 10 to 15% of persons with familial 
pneumothorax, is associated with renal cancer.3 
Spontaneous pneumothorax is also a complica-
tion of certain genetic disorders that affect the 
integrity of connective tissue, transforming 
growth factor β signaling, or both. These dis-
orders include Marfan’s syndrome, the Loeys–
Dietz syndrome, vascular Ehlers–Danlos syn-
drome, and homocystinuria. Moreover, inhibition 
of mechanistic target of rapamycin (mTOR) is a 
therapeutic target for pulmonary disease in tuber-
ous sclerosis and lymphangioleiomyomatosis.4
The identification of a genetic disorder that 
predisposes to pneumothorax is valuable in guid-
ing surveillance for life-threatening extratho-
racic manifestations and in counseling at-risk 
family members. Identification of molecular 
mechanisms presents possible therapeutic targets.
Houriya Ayoubieh, M.D. 
Eyas Alkhalili, M.D
Johns Hopkins University 
Baltimore, MD
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To the Editor: Feller-Kopman and Light did not 
mention two possible therapeutic options for re-
fractory hepatic hydrothorax. These options are 
placement of a transjugular intrahepatic porto-
systemic shunt (TIPS) and liver transplantation.
The use of a TIPS has been investigated in a 
number of uncontrolled studies and several case 
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